Physician profile
Mark D Bennett
NPI 1861467599
$2,076.43
in general payments reported to CMS, 2019-2025
8 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $219 · 2021: $84.11 · 2022: $183 · 2023: $351 · 2024: $56.78 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Entertainment: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.97 |
| Entertainment | $252.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $863.19 | 2019-2025 | Total30, Precision 1, Precision7 |
| Bausch & Lomb Americas INC. | $319.90 | 2022-2025 | Miebo, Infuse |
| Optos, INC. | $288.34 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $210.11 | 2022-2025 | Clariti Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $132.26 | 2020-2024 | Acuvue |
| Abb Con-Cise Optical Group LLC | $109.61 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Optovue, INC. | $91.01 | 2020 | |
| Eyevance Pharmaceuticals LLC | $62.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.